Overview

Viral Vectors and Plasmid DNA Manufacturing Market is poised to value over CAGR of over 18.8% during the forecast period 2022 to 2028.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Viral Vectors and Plasmid DNA Manufacturing Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Viral Vectors and Plasmid DNA Manufacturing Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Viral Vectors and Plasmid DNA Manufacturing Market:
• Merck KGaA
• Lonza
• FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
• Cobra Biologics Ltd.
• Brammer Bio
• Waisman Biomanufacturing
• Genezen
• YPOSKESI
• Advanced BioScience Laboratories, Inc. (ABL, Inc.)
• Novasep Holding S.A.S
• ATVIO Biotech Ltd
• Vigene Biosciences, Inc.
• General Electric Company (GE Healthcare)
• CEVEC Pharmaceuticals GmbH
• Batavia Biosciences B.V.
• Biovian Oy
• Wuxi AppTec Co., Ltd.
• VGXI, Inc
• Paragon Bioservices, Inc
• Miltenyi Biotec GmbH
• SIRION Biotech GmbH
• Virovek Incorporation
• BioNTech IMFS GmbH
• VIVEbiotech S.L.
• Creative Biogene
• Vibalogics GmbH
 (Note: The list of the major players will be updated with the latest market scenario and trends)

Viral Vectors and Plasmid DNA Manufacturing Market Segmentation:
By Vector Type
• Adenovirus
• Retrovirus
• Plasmid DNA
• AAV
• Lentivirus
• Others
By Workflow
• Upstream Processing
 o Vector Amplification & Expansion
 o Vector Recovery/Harvesting
• Downstream Processing
 o Purification
 o Fill-finish
By Application
• Antisense & RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology
By Disease
• Cancer
• Genetic Disorders
• Infectious Diseases
• Others
By End-use
• Pharmaceutical and Biopharmaceutical Companies
• Research Institutes
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Viral Vectors and Plasmid DNA Manufacturing Market By Vector Type, By Workflow, By Application, By Disease,  By End-use and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
  1.1 Objectives of the Study
  1.2 Market Definition
  1.3 Market Scope
      1.3.1 Years Considered for the Study
      1.3.2 Market Covered
  1.4 Currency
  1.5 Limitations
  1.6 Stakeholders

2. Research Methodology
   2.1 Research Data
       2.1.1 Secondary Data
             2.1.1.1 Key Data from Secondary Sources
       2.1.2 Primary Data
             2.1.2.1 Key Data from Primary Sources
   2.2 Market Size Estimation
   2.3 Market Breakdown and Data Triangulation
   2.4 Assumptions for the Study  

3. Executive Summary
  3.1 Market Outlook
  3.2 Segment Outlook
  3.3 Competitive Insights

4. Global Viral Vectors and Plasmid DNA Manufacturing Market Variables, Trends & Scope
  4.1. Market Lineage Outlook
  4.2. Penetration and Growth Prospect Mapping
  4.3. Industry Value Chain Analysis
  4.4. Cost Analysis Breakdown
  4.5. Technology Overview
  4.6. Regulatory Framework
       4.6.1. Reimbursement Framework
       4.6.2. Standards and Compliances

5. Market Overview
  5.1. Market Dynamics
       5.1.1. Market Driver Analysis
              5.1.1.1. Increasing focus of Viral Vectors and Plasmid DNA Manufacturing Companies on Brand Protection
              5.1.1.2. Untapped Opportunities in Emerging Regions
       5.1.2. Market Restraint Analysis
              5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
       5.1.3. Industry Challenges
              5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Viral Vectors and Plasmid DNA Manufacturing Market Analysis Tools
  6.1. Industry Analysis - Porter’s
       6.1.1. Supplier Power
       6.1.2. Buyer Power
       6.1.3. Substitution Threat
       6.1.4. Threat from New Entrants
       6.1.5. Competitive Rivalry
  6.2. Pestel Analysis
       6.2.1. Political Landscape
       6.2.2. Environmental Landscape
       6.2.3. Social Landscape
       6.2.4. Technology Landscape
       6.2.5. Legal Landscape
  6.3. Major Deals And Strategic Alliances Analysis
       6.3.1. Joint Ventures
       6.3.2. Mergers and Acquisitions
       6.3.3. Licensing and Partnership
       6.3.4. Technology Collaborations
       6.3.5. Strategic Divestments
  6.4. Market Entry Strategies
  6.5. Case Studies

7. Global Viral Vectors and Plasmid DNA Manufacturing Market, By Vector Type Historical Analysis and Forecast 2022-2028 (USD Million)
  7.1. Adenovirus
  7.2. Retrovirus
  7.3. Plasmid DNA
  7.4. AAV
  7.5. Lentivirus
  7.6. Others

8. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Workflow Historical Analysis and Forecast 2022-2028 (USD Million)
  8.1. Upstream Processing
       8.1.1. Vector Amplification & Expansion
       8.1.2. Vector Recovery/Harvesting
  8.2. Downstream Processing
       8.2.1. Purification
       8.2.2. Fill-finish

9. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Application Historical Analysis and Forecast 2022-2028 (USD Million)
  9.1. Antisense & RNAi
  9.2. Gene Therapy
  9.3. Cell Therapy
  9.4. Vaccinology

10. Global Viral Vectors and Plasmid DNA Manufacturing Market, by Disease Historical Analysis and Forecast 2022-2028 (USD Million)
  10.1. Cancer
  10.2. Genetic Disorders
  10.3. Infectious Diseases
  10.4. Others

11. Global Viral Vectors and Plasmid DNA Manufacturing Market, by End-use Historical Analysis and Forecast 2022-2028 (USD Million)
  11.1. Pharmaceutical and Biopharmaceutical Companies
  11.2. Research Institutes

12. North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
  12.1. Introduction
  12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
       12.2.1. U.S.A
       12.2.2. Canada
       12.2.3. Mexico
  12.3. Market Size (USD Million) Forecast for North America 2022-2028

13. Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   13.1. Introduction
   13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         13.2.1. Brazil
         13.2.2. Venezuela
         13.2.3. Argentina
         13.2.4. Rest of Latin America
   13.3. Market Size (USD Million) Forecast for Latin America 2022-2028

14. Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   14.1. Introduction
   14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         14.2.1. Germany
         14.2.2. U.K        
         14.2.3. France
         14.2.4. Italy
         14.2.5. Spain
         14.2.6. Russia
         14.2.7. Poland
         14.2.8. Rest of Europe
   14.3. Market Size (USD Million) Forecast for Europe 2022-2028

15. Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   15.1. Introduction
   15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         15.2.1. Japan
         15.2.2. China
         15.2.3. India
         15.2.4. Australia and New Zealand
         15.2.5. ASEAN
         15.2.6. Rest of Asia Pacific
   15.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

16. Middle East and Africa Market Analysis 2016–2020 and Forecast 2022–2028 (USD Million)
   16.1. Introduction
   16.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
         16.2.1. GCC
         16.2.2. Israel
         16.2.3. South Africa
         16.2.4. Rest of MEA
   16.3. Market Size (USD Million) Forecast for MEA 2022-2028

17. Market Share Analysis and Competitive Landscape  
   17.1. Global Landscape - Key Players, Revenue and Presence
   17.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
   17.3. Global Emerging Companies
   17.4. North America - Market Share Analysis and Key Regional Players
   17.5. Europe - Market Share Analysis and Key Regional Players
   17.6. Asia Pacific - Market Share Analysis and Key Regional Players
   17.7. Global Key Player - Growth Matrix

18. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   18.1. Merck KGaA
         18.1.1. Company Overview
         18.1.2. Product Portfolio
         18.1.3. SWOT Analysis
         18.1.4. Financial Overview
         18.1.5. Strategic Overview
   18.2. Lonza
         18.2.1. Company Overview
         18.2.2. Product Portfolio
         18.2.3. SWOT Analysis
         18.2.4. Financial Overview
         18.2.5. Strategic Overview
   18.3. FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
         18.3.1. Company Overview
         18.3.2. Product Portfolio
         18.3.3. SWOT Analysis
         18.3.4. Financial Overview
         18.3.5. Strategic Overview
   18.4. Cobra Biologics Ltd.
         18.4.1. Company Overview
         18.4.2. Product Portfolio
         18.4.3. SWOT Analysis
         18.4.4. Financial Overview
         18.4.5. Strategic Overview
   18.5 Brammer Bio
         18.5.1. Company Overview
         18.5.2. Product Portfolio
         18.5.3. SWOT Analysis
         18.5.4. Financial Overview
         18.5.5. Strategic Overview          
   18.6 Waisman Biomanufacturing
         18.6.1. Company Overview
         18.6.2. Product Portfolio
         18.6.3. SWOT Analysis
         18.6.4. Financial Overview
         18.6.5. Strategic Overview      
   18.7. Genezen
         18.7.1. Company Overview
         18.7.2. Product Portfolio
         18.7.3. SWOT Analysis
         18.7.4. Financial Overview
         18.7.5. Strategic Overview
   18.8. YPOSKESI
         18.8.1. Company Overview
         18.8.2. Product Portfolio
         18.8.3. SWOT Analysis
         18.8.4. Financial Overview
         18.8.5. Strategic Overview
   18.9. Advanced BioScience Laboratories, Inc. (ABL, Inc.)
         18.9.1. Company Overview
         18.9.2. Product Portfolio
         18.9.3. SWOT Analysis
         18.9.4. Financial Overview
         18.9.5. Strategic Overview
   18.10.Novasep Holding S.A.S
         18.10.1. Company Overview
         18.10.2. Product Portfolio
         18.10.3. SWOT Analysis
         18.10.4. Financial Overview
         18.10.5. Strategic Overview
   18.11.ATVIO Biotech Ltd.
         18.11.1. Company Overview
         18.11.2. Product Portfolio
         18.11.3. SWOT Analysis
         18.11.4. Financial Overview
         18.11.5. Strategic Overview
   18.12.Vigene Biosciences, Inc.
         18.12.1. Company Overview
         18.12.2. Product Portfolio
         18.12.3. SWOT Analysis
         18.12.4. Financial Overview
         18.12.5. Strategic Overview
   18.13.General Electric Company (GE Healthcare)
         18.13.1. Company Overview
         18.13.2. Product Portfolio
         18.13.3. SWOT Analysis
         18.13.4. Financial Overview
         18.13.5. Strategic Overview
   18.14.CEVEC Pharmaceuticals GmbH
         18.14.1. Company Overview
         18.14.2. Product Portfolio
         18.14.3. SWOT Analysis
         18.14.4. Financial Overview
         18.14.5. Strategic Overview
   18.15.Batavia Biosciences B.V.
         18.15.1. Company Overview
         18.15.2. Product Portfolio
         18.15.3. SWOT Analysis
         18.15.4. Financial Overview
         18.15.5. Strategic Overview          
   18.16.Biovian Oy
         18.16.1. Company Overview
         18.16.2. Product Portfolio
         18.16.3. SWOT Analysis
         18.16.4. Financial Overview
         18.16.5. Strategic Overview      
   18.17.Wuxi AppTec Co., Ltd.
         18.17.1. Company Overview
         18.17.2. Product Portfolio
         18.17.3. SWOT Analysis
         18.17.4. Financial Overview
         18.17.5. Strategic Overview
   18.18.VGXI, Inc.
         18.18.1. Company Overview
         18.18.2. Product Portfolio
         18.18.3. SWOT Analysis
         18.18.4. Financial Overview
         18.18.5. Strategic Overview
   18.19.Paragon Bioservices, Inc.
         18.19.1. Company Overview
         18.19.2. Product Portfolio
         18.19.3. SWOT Analysis
         18.19.4. Financial Overview
         18.19.5. Strategic Overview
   18.20.Miltenyi Biotec GmbH
         18.20.1. Company Overview
         18.20.2. Product Portfolio
         18.20.3. SWOT Analysis
         18.20.4. Financial Overview
         18.20.5. Strategic Overview
   18.21.SIRION Biotech GmbH
         18.21.1. Company Overview
         18.21.2. Product Portfolio
         18.21.3. SWOT Analysis
         18.21.4. Financial Overview
         18.21.5. Strategic Overview
   18.22.Virovek Incorporation
         18.22.1. Company Overview
         18.22.2. Product Portfolio
         18.22.3. SWOT Analysis
         18.22.4. Financial Overview
         18.22.5. Strategic Overview
   18.23.BioNTech IMFS GmbH
         18.23.1. Company Overview
         18.23.2. Product Portfolio
         18.23.3. SWOT Analysis
         18.23.4. Financial Overview
         18.23.5. Strategic Overview
   18.24.VIVEbiotech S.L.
         18.24.1. Company Overview
         18.24.2. Product Portfolio
         18.24.3. SWOT Analysis
         18.24.4. Financial Overview
         18.24.5. Strategic Overview
   18.25.Creative Biogene
         18.25.1. Company Overview
         18.25.2. Product Portfolio
         18.25.3. SWOT Analysis
         18.25.4. Financial Overview
         18.25.5. Strategic Overview  
   18.26.Vibalogics GmbH
         18.26.1. Company Overview
         18.26.2. Product Portfolio
         18.26.3. SWOT Analysis
         18.26.4. Financial Overview
         18.26.5. Strategic Overview              

19. Pre and Post COVID-19 Impact
   19.1. Positive influence on the healthcare industry
   19.2. The financial disruption of the manufacturing sector
   19.3. Impact of COVID-19 on emerging companies
   19.4. Significant mandates in the healthcare regulations initiated by administrations
   19.5. The overall economic slowdown of the developing and developed nations

20. FutureWise SME Key Takeaway Points for Client

Tables

Figures